MAGELLAN LONGEVITY
HomeResearchStudy library › Effectiveness and safety of non-steroidal anti-inflammatory drugs…
Study summary · Pain, nerves & musculoskeletal medicine

What are the effectiveness and safety profiles of different NSAID, opioid, and paracetamol preparations and doses for knee and hip osteoarthritis pain and physical function?

In one paragraph

Diclofenac Topical Gel, a network meta-analysis in 102,829 participants (BMJ 2021, PMID 34642179) — increased risk of dropouts due to adverse events was observed in 18.5% of oral NSAIDs, 0% of topical NSAIDs, and 83.3% of opioids. Topical diclofenac is a safer and effective first-line option for knee osteoarthritis, while some oral NSAIDs are effective but carry higher risks, and opioids generally offer more harm than benefit.

Source: BMJ 2021, PMID 34642179 ↗ · Research map · How Magellan grades evidence · evidence confidence: medium

BMJ · 2021 · PMID 34642179 · DOI 10.1136/bmj.n2321

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

Topical diclofenac is a safer and effective first-line option for knee osteoarthritis, while some oral NSAIDs are effective but carry higher risks, and opioids generally offer more harm than benefit.

The question

What are the effectiveness and safety profiles of different NSAID, opioid, and paracetamol preparations and doses for knee and hip osteoarthritis pain and physical function?

What they tested

The study aimed to identify effective and safe drug options at their lowest possible doses for osteoarthritis.

How they did it

This was a systematic review and network meta-analysis of 192 randomized trials, comprising 102,829 participants, published in English with at least 100 patients per group. The trials evaluated NSAIDs, opioids, or paracetamol for osteoarthritis. Data on pain, physical function, and safety outcomes were extracted and assessed for bias. Bayesian random effects models were used for network meta-analysis, comparing active treatments to oral placebo.

What they found

Five oral preparations (diclofenac 150 mg/day, etoricoxib 60 and 90 mg/day, rofecoxib 25 and 50 mg/day) had a ≥99% probability of exceeding the minimal clinically relevant pain reduction. Topical diclofenac (70-81 and 140-160 mg/day) had a ≥92.3% probability, while all opioids had a ≤53% probability of achieving this pain reduction. Increased risk of dropouts due to adverse events was observed in 18.5% of oral NSAIDs, 0% of topical NSAIDs, and 83.3% of opioids. An increased risk of any adverse event was found in 29.8% of oral NSAIDs, 0% of topical NSAIDs, and 89.5% of opioids. Oxymorphone 80 mg/day showed the highest risk for dropouts due to adverse events (51%) and any adverse event (88%).

Probability of Treatment Effect Exceeding Minimal Clinically Relevant Pain Reduction
Values shown: Probability (%)
Oral NSAIDs (5 preparations)99
Topical Diclofenac (70-81 & 140-160 mg/day)92.3
All Opioids53

Probability of different drug categories achieving a more pronounced treatment effect than the minimal clinically relevant reduction in pain.

What it means

Etoricoxib 60 mg/day and diclofenac 150 mg/day appear to be the most effective oral NSAIDs for osteoarthritis pain and function, but may not be suitable for long-term use or patients with comorbidities due to increased adverse event risk. Topical diclofenac 70-81 mg/day is effective and generally safer, making it a potential first-line treatment for knee osteoarthritis. The harms of opioid treatment for osteoarthritis likely outweigh its clinical benefits.

Limitations

The abstract does not explicitly state limitations of the study beyond the inherent risks associated with certain treatments for specific patient populations.

Where the published abstract does not list limitations, we say so rather than inventing them. Read the full paper on PubMed before drawing conclusions.

“Topical diclofenac (70–81 and 140–160 mg/day) had ≥92.3% probability of more pronounced treatment effects than the minimal clinically relevant reduction in [osteoarthritis] pain.”— from the published abstract, BMJ 2021

The paper at a glance

TitleEffectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis
JournalBMJ
Year2021
PMID34642179 ↗
DOI10.1136/bmj.n2321 ↗
TopicPain, nerves & musculoskeletal medicine

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

Diclofenac Topical Gel

Chronic joint pain limits movement, and lost mobility accelerates the muscle loss, weight gain and inflammation that shorten healthspan. By calming COX-driven inflammation locally, topical diclofenac helps people stay active with fewer of the gastrointestinal and cardiovascular risks of oral NSAIDs.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). What are the effectiveness and safety profiles of different NSAID, opioid, and paracetamol preparations and doses for knee and hip osteoarthritis pain and physical function? [Plain-English summary of BMJ 2021, PMID 34642179, DOI 10.1136/bmj.n2321]. Magellan Longevity. https://magellanlongevity.com/study/diclofenac_oa.html
BibTeX
@misc{magellan_diclofenac_oa, title = {What are the effectiveness and safety profiles of different NSAID, opioid, and paracetamol preparations and doses for knee and hip osteoarthritis pain and physical function?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/diclofenac_oa.html}}, note = {Plain-English summary of PubMed PMID 34642179; DOI 10.1136/bmj.n2321; BMJ 2021. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/diclofenac_oa.html

Related studies in the Magellan library

All 14 Magellan summaries on pain, nerves & musculoskeletal medicine →

How this summary was made. Every section above restates what the published abstract of PMID 34642179 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.